Current approaches to the diagnosis and management of Beckwith–Wiedemann syndrome in newborns

Authors:

Abstract
Beckwith–Wiedemann syndrome (OMIM 130650, Q87.3) is a congenital anomaly characterized by overgrowth. It has a wide range of clinical manifestations, but the three main features include macrosomia, macroglossia, and anterior abdominal wall defect. The prevalence of the disease is 1 in 13,700 newborns worldwide, equally represented in males and females. Epigenetic and genetic changes on chromosome 11p15.5 are etiological factors: loss of maternal methylation at IC2 (KCNQ1OT1), paternal uniparental disomy, mutation in the CDKN1C gene, maternal hypermethylation at IC1 (H19), cytogenetically visible duplication of chromosome 11p15, and translocation/inversion of chromosome 11p15. Genetic heterogeneity and the possibility of cellular mosaicism in this syndrome cause phenotypic differences between patients, as well as the complexity of molecular genetic confirmation. An important aspect in the management of patients with Beckwith-Wiedemann syndrome is timely detection and correction of hypoglycemia as a predictor of neurological deficit, as well as long-term monitoring for early detection of malignant neoplasms, including Wilms tumor. Treatment is currently symptomatic, including therapeutic and surgical management, but potential approaches to targeted therapy are being explored. Timely diagnosis of the disease improves longterm outcomes and quality of life of children with this pathology. This article presents current approaches to the diagnosis and management of Beckwith–Wiedemann syndrome in newborns. Key words: genomic imprinting disorders, hypoglycemia, anterior abdominal wall defect, macroglossia, macrosomia, Wilms tumor, Beckwith–Wiedemann syndrome